What is DSI?
Headquartered in St. Paul, Minnesota, DSI provides a comprehensive preclinical platform designed to capture and interpret physiological data from research animals. The company's product ecosystem is anchored by sophisticated telemetry systems, advanced pulmonary solutions, and integrated software platforms. By bridging the gap between raw biological data and actionable research insights, DSI serves as a critical partner for pharmaceutical companies, contract research organizations, and academic institutions globally. Their technological suite is essential for drug discovery and safety pharmacology, ensuring that researchers maintain high-fidelity data streams throughout the development lifecycle.
How much funding has DSI raised?
DSI has raised a total of $12M across 1 funding round:
Series A
$12M
Series A (2002): $12M, investors not publicly disclosed
Key Investors in DSI
Undisclosed Investors
What's next for DSI?
With this latest infusion of capital, DSI is well-positioned to accelerate its innovation roadmap, focusing on the integration of artificial intelligence into its existing software platforms to enhance data throughput and predictive accuracy. The strategic allocation of these funds will likely prioritize the expansion of their pulmonary research capabilities and the scaling of their global service operations. As the demand for high-precision preclinical data grows, DSI is poised to leverage its established market presence to capture emerging opportunities in personalized medicine and complex disease modeling. The company remains committed to advancing the standards of physiological monitoring, ensuring that its clients can navigate the complexities of modern drug development with greater efficiency and scientific rigor.
See full DSI company page
